Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 81Gastrointestinal 60Tumor-Agnostic 48Gynecologic 43Genitourinary 40Thoracic 38Head & Neck 32Lymphoid 21CNS 20Other hematologic neoplasm 17Dermatologic 17Other 12Sarcoma 9Plasma cell 9Other solid neoplasm 7Classical hematology 6Myeloid 5Other neoplasm 4Endocrine 3NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Surveys and Questionnaires × NET × Clear all
NCT03289741 2025-05-09

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Center

Phase 4 Completed
51 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡